Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Daniel M. Hartung, PharmD, MPH
Advertisement
Articles by Daniel M. Hartung, PharmD, MPH
Little is known about opioid prescribing patterns in patients with chronic overlapping pain conditions. This study suggests target populations for interventions to manage chronic pain.
Advertisement
Latest Updated Articles
Budget Impact Analysis of Biosimilar Natalizumab in the USPublished: May 17th 2024 | Updated:
- Chronic Overlapping Pain Conditions and Long-term Opioid Treatment
Published: May 17th 2023 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Leucovorin Treatment Expansion for Autism Symptoms Under FDA Review
2
Contributor: Medication Adherence as a Journey—A Year-Round Strategy for Medicare Advantage Success
3
US, Japan Patients With Diabetes Discontinue Semaglutide After First Year
4
How Clinician-Led Partnerships Strengthen Post-Acute Care
5
